Float Short %

24.82

Margin Of Safety %

Put/Call OI Ratio

0.16

EPS Next Q Diff

0.06

EPS Last/This Y

0.6

EPS This/Next Y

0.54

Price

5.9

Target Price

23.77

Analyst Recom

1.4

Performance Q

-36.93

Relative Volume

0.86

Beta

0.56

Ticker: IOVA

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	IOVA	7.21	0.29	0.17	253827
2024-12-20	IOVA	7.38	0.28	0.06	254520
2024-12-23	IOVA	7.45	0.32	0.15	211825
2024-12-24	IOVA	7.49	0.32	0.22	213339
2024-12-26	IOVA	7.59	0.32	0.10	214701
2024-12-27	IOVA	7.38	0.31	0.07	219140
2024-12-30	IOVA	7.16	0.31	0.05	218086
2024-12-31	IOVA	7.41	0.30	0.23	214104
2025-01-02	IOVA	7.79	0.31	0.13	218182
2025-01-03	IOVA	7.64	0.30	0.13	223073
2025-01-06	IOVA	7.47	0.29	0.07	225324
2025-01-07	IOVA	7.38	0.28	0.60	233214
2025-01-08	IOVA	7.17	0.29	0.58	237684
2025-01-09	IOVA	7.17	0.29	0.60	237684
2025-01-10	IOVA	6.38	0.28	0.04	239261
2025-01-13	IOVA	5.78	0.26	0.08	257931
2025-01-14	IOVA	5.89	0.25	0.12	258829
2025-01-15	IOVA	5.91	0.24	0.12	261928
2025-01-16	IOVA	5.75	0.19	2.29	252582
2025-01-17	IOVA	5.91	0.16	0.12	247529
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	IOVA	7.21	41.9	95.2	-1.29
2024-12-20	IOVA	7.38	41.9	83.2	-1.29
2024-12-23	IOVA	7.46	41.9	87.6	-1.29
2024-12-24	IOVA	7.49	41.9	90.4	-1.29
2024-12-26	IOVA	7.60	41.9	86.2	-1.29
2024-12-27	IOVA	7.38	41.9	103.5	-1.29
2024-12-30	IOVA	7.16	41.9	102.8	-1.29
2024-12-31	IOVA	7.41	41.9	78.6	-1.29
2025-01-02	IOVA	7.78	41.9	71.7	-1.29
2025-01-03	IOVA	7.64	41.9	99.4	-1.29
2025-01-06	IOVA	7.47	41.9	101.4	-1.29
2025-01-07	IOVA	7.39	41.9	97.0	-1.29
2025-01-08	IOVA	7.17	41.9	104.1	-1.29
2025-01-09	IOVA	7.17	41.9	91.9	-1.29
2025-01-10	IOVA	6.39	41.9	134.9	-1.29
2025-01-13	IOVA	5.78	41.9	131.1	-1.29
2025-01-14	IOVA	5.89	41.9	84.1	-1.29
2025-01-15	IOVA	5.91	41.9	90.4	-1.29
2025-01-16	IOVA	5.75	41.9	103.0	-1.29
2025-01-17	IOVA	5.90	40.3	81.9	-1.29
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	IOVA	-0.09	1.73	23.04
2024-12-20	IOVA	-0.09	1.73	23.04
2024-12-23	IOVA	-0.08	1.73	23.04
2024-12-24	IOVA	-0.08	1.73	23.04
2024-12-26	IOVA	-0.09	1.73	24.02
2024-12-27	IOVA	-0.09	1.73	24.02
2024-12-30	IOVA	-0.09	1.75	24.02
2024-12-31	IOVA	-0.09	1.75	24.02
2025-01-02	IOVA	-0.08	1.75	24.02
2025-01-03	IOVA	-0.09	1.75	24.02
2025-01-06	IOVA	-0.09	1.76	24.02
2025-01-07	IOVA	-0.09	1.76	24.02
2025-01-08	IOVA	-0.09	1.76	24.02
2025-01-09	IOVA	-0.09	1.76	24.02
2025-01-10	IOVA	-0.09	1.76	24.02
2025-01-13	IOVA	-0.09	1.73	24.82
2025-01-14	IOVA	-0.09	1.73	24.82
2025-01-15	IOVA	-0.09	1.73	24.82
2025-01-16	IOVA	-0.09	1.73	24.82
2025-01-17	IOVA	-0.09	1.73	24.82
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.26

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

-0.09

Institutional Transactions

1.73

Beta

0.56

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

89.1

Max Drawdown 5-Year %

-93.7

Target Price

23.77

P/E

Forward P/E

PEG

P/S

19.82

P/B

2.33

P/Free Cash Flow

EPS

-1.5

Average EPS Est. Cur. Y

-1.29

EPS Next Y. (Est.)

-0.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-451.25

Relative Volume

0.86

Return on Equity vs Sector %

-72.1

Return on Equity vs Industry %

-59.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

81.9

Iovance Biotherapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 557

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

stock quote shares IOVA – Iovance Biotherapeutics, Inc. Stock Price stock today

news today IOVA – Iovance Biotherapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch IOVA – Iovance Biotherapeutics, Inc. yahoo finance google finance

stock history IOVA – Iovance Biotherapeutics, Inc. invest stock market

stock prices IOVA premarket after hours

ticker IOVA fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IOVA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y